CN112521508A

CN112521508A - CD20 antibody and application thereof in treating cancer

Info

Publication number: CN112521508A
Application number: CN202011592430.9A
Authority: CN
Inventors: 刘欢; 戴伟利
Original assignee: Beijing Guangwei Biotechnology Co Ltd
Current assignee: Chenzhou binze medical laboratory Co.,Ltd.
Priority date: 2020-12-29
Filing date: 2020-12-29
Publication date: 2021-03-19
Anticipated expiration: 2040-12-29
Also published as: CN112521508B

Abstract

The invention relates to a CD20 antibody and application thereof in treating cancer, and provides a novel CD20 antibody and preparation and application thereof. Wherein the antibody is capable of better binding to human CD20 protein, inducing strong CDC killing activity while having a degree of cell death-inducing activity.

Description

CD20 antibody and application thereof in treating cancer

Technical Field

The invention relates to the field of biological medicines, in particular to a CD20 antibody and application thereof in treating cancers.

Technical Field

Cell lymphoma is a solid tumor that occurs in cells, and can be mainly classified into Hodgkin's Lymphoma (HL) and Non-Hodgkin's lymphoma (NHL). Is very common in malignant tumors of the blood system, and poses extremely serious threat to human life health. The B lymphocyte antigen CD20 is a unique marker on the surface of human B lymphocytes and consists essentially of 297 amino acids. The molecular weight of CD20 is 33-37KD, which belongs to non-glycosylated phosphoprotein according to different phosphorylation levels. The CD20 molecule is a transmembrane protein with four transmembrane domains, with both the N-and C-termini located inside the cytoplasm. The main epitope of the CD20 molecule is located between the third and fourth transmembrane regions, and is a circular region of 43 amino acids. From precursor B cells to the subsequent differentiation process, CD20 is widely expressed on the surface of B cells, but not in late-differentiated plasma cells. CD20 is expressed in all but the first and last stages of B cell development. Found in B cell lymphoma, hairy cell leukemia, B cell chronic lymphocytic leukemia and melanoma tumor stem cells. The CD20 molecule is located on the surface of cell membrane, and the steric hindrance of the antibody access is small, so that the CD20 molecule becomes an ideal target for treating cell lymphoma.

Rituximab (rituximab) was the first mab drug approved by the U.S. Food and Drug Administration (FDA) for marketing and use in treating NHL. However, because the Rituximab molecule contains 30% of the murine sequence, the patient is easy to cause the human anti-mouse antibody immune response (HAMA) and generate serious adverse reaction after long-term administration. Meanwhile, the clinical response rate of Rituximab is only 50%, and the complete remission rate is only 10%. Therefore, the long-term application of Rituximab in clinic is severely restricted.

Disclosure of Invention

Based on the above findings, the present invention provides a humanized antibody that has low immunogenicity, is capable of better binding to human CD20 protein, and has good CDC activity.

The invention provides the following technical scheme:

an isolated monoclonal antibody (e.g., a humanized antibody) comprises a light chain variable region comprising a CDR1 region, a CDR2 region, and a CDR3 region, wherein the light chain CDR1, CDR2, and CDR3 regions comprise SEQ ID NOs 3, 4, and 5; further comprising a heavy chain variable region comprising the CDR1 region, CDR2 region and CDR3 region, the heavy chain CDR1 region, CDR2 region and CDR3 region comprise SEQ ID NOs 6, 7 and 8, respectively; wherein the antibody, or antigen-binding portion thereof, binds to CD 20.

In some embodiments, the antibodies of the invention comprise a heavy chain variable region and a light chain variable region, wherein the light chain variable region sequence is SEQ ID NO 1 and the heavy chain variable region sequence is SEQ ID NO 2; wherein the antibody, or antigen-binding portion thereof, binds to CD 20.

In some embodiments, the antibodies of the invention comprise a heavy chain comprising a heavy chain variable region and a heavy chain constant region and a light chain comprising a light chain variable region and a light chain constant region, wherein the heavy chain variable region and the light chain variable region comprise the amino acid sequences described above and the light chain constant region and heavy chain constant region comprise the amino acid sequences of SEQ ID NOs 9 and 10, respectively, and wherein the antibody or antigen-binding portion thereof binds to CD 20.

In some embodiments, the antibodies of the invention comprise or consist of two heavy chains and two light chains, wherein each heavy chain comprises a heavy chain constant region sequence, a heavy chain variable region sequence, or a CDR sequence as described above, and each light chain comprises a light chain constant region sequence, a light chain variable region sequence, or a CDR sequence as described above. The antibody of the invention may be a full length antibody, for example of the IgG1, IgG2 or IgG4 subtype. In some embodiments, the antibodies of the invention may be single chain antibodies, or may be comprised of antibody fragments, such as Fab or Fab' 2 fragments.

In some embodiments, the CD20 antibody light chain constant region of the present invention is further preferably a kappa chain. The antibody heavy chain constant region is further preferably IgG 1.

In some embodiments, the anti-CD 20 antibodies or fragments thereof of the invention specifically bind to human CD 20.

In some embodiments, the anti-CD 20 antibodies of the invention are capable of inducing strong CDC activity.

In some embodiments, the anti-CD 20 antibodies of the invention have the ability to induce death of cells expressing CD 20.

In some embodiments, the anti-CD 20 antibodies of the invention are capable of inhibiting the growth, proliferation, and anti-tumor activity of tumor cells.

In some embodiments, the binding of a CD20 antibody of the invention to human CD20 is determined by an Elisa or flow cytometry (e.g., FACS) assay.

The invention provides a pharmaceutical combination comprising a CD20 antibody of the invention, and further comprising a second drug or active agent. The second drug can be anti-tumor drug, such as platinum compound such as cisplatin, carboplatin, platinum oxalate, etc., mitomycin (MMC), dihydrofolate reductase inhibitor such as Methotrexate (MTX), tamoxifen, droloxifene, exemestane, aminoglutethimide, Lantrexone, letrozole, ryanodine, etc., norrad, etanerone, interleukin-2; thymopeptides, anti-PD-1 antibodies, anti-HER 2 antibodies, anti-LAG-3 antibodies, anti-CTLA-4 antibodies, anti-GITR antibodies, and/or anti-PD-L1 antibodies.

The CD20 antibody can be applied to preparation of a medicament for treating CD20 related diseases, wherein the diseases are selected from hematological tumors, solid tumors or a combination thereof, and comprise non-Hodgkin lymphoma (NHL), Acute Myelocytic Leukemia (AML), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Acute Lymphoblastic Leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), Hodgkin Lymphoma (HL), gastric cancer peritoneal metastasis, liver cancer, leukemia, renal tumors, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, large intestine cancer, cervical cancer, ovarian cancer, lymphatic cancer, nasopharyngeal cancer, adrenal gland tumor, bladder tumor, non-small cell lung cancer (NSCLC), brain glioma, endometrial cancer or a combination thereof.

The term "anti-CD 20 antibody" as used herein refers to an antibody that is capable of binding human CD20 protein or fragment thereof with sufficient affinity such that the antibody can be used as a diagnostic and/or therapeutic agent targeting human CD 20.

The term "antibody" as used herein includes any moiety having immunoglobulin-like binding function. The term includes whole antibody molecules and any antigen-binding fragment (i.e., "antigen-binding portion") or single chain thereof, camelid antibodies including, for example, nanobodies, phage display binding constructs, and the like. A natural "antibody" comprises at least one heavy (H) chain and one light (L) chain. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region. The heavy chain constant region consists of three domains, CH1, CH2, and CH 3. Each light chain consists of a light chain variable region (VL) and a light chain constant region. The light chain constant region consists of one domain CL. The VH and VL regions can be further subdivided into hypervariable regions known as Complementarity Determining Regions (CDRs), interspersed with more conserved regions known as Framework (FR) or junction (J) regions (JH or JL in heavy and light chains, respectively).

The term "monoclonal antibody" as used herein refers to an antibody derived from a single copy or clone, e.g., of a eukaryotic, prokaryotic, or phage clone, and not to the method by which it is produced. The monoclonal antibody or antigen-binding fragment thereof can be produced, for example, by hybridoma technology, recombinant technology, phage display technology, synthetic techniques such as CDR grafting, or the like or otherwise.

The five major classes of antibodies, IgA, IgD, IgE, IgG and IgM, are known in the art, and several of these antibodies can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA 2. The heavy chain constant domains corresponding to different classes of immunoglobulins are called α, δ, ε, γ and μ, respectively.

The term "CDR region" or "complementarity determining region" as used herein refers to the amino acid residues of an antibody that are responsible for antigen binding. CDR region sequences can be defined by Kabat, Chothia method definition or the field of any known CDR region sequence determination method and identification of the variable region within amino acid residues. The methods used in the present invention may utilize or be defined according to CDRs defined by any of these methods, including but not limited to any of the Kabat definitions, Chothia definitions. In particular, the CDR sequences provided herein are according to the Kabat definition.

The term "humanized antibody" as used herein generally refers to an antibody that is specific for CD20 (e.g., a murine antibody or an antibody produced by a hybridoma) having VH-CDR and VL-CDR sequences grafted onto selected human antibody framework coding sequences to produce a humanized antibody. Optionally, the CDR regions can be optimized by random mutagenesis or mutagenesis at specific positions to replace one or more amino acids in the CDR with different amino acids prior to grafting the CDR regions into the framework regions. Alternatively, the CDR regions can be optimized after insertion into the human framework regions using methods available to those skilled in the art. Preferably, a "humanized antibody" has CDRs derived from or derived from a parent antibody (i.e., a non-human antibody, preferably a mouse monoclonal antibody) to the extent that they are present in which the framework and constant region (or a major or substantial portion thereof, i.e., at least about 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99%) sequences are homologous to human germline immunoglobulin regions or recombinant or mutated forms thereof, regardless of whether the antibody is produced in a human cell.

The term "K" as used herein_assoc"or" K_a"means the association ratio of a particular antibody-antigen interaction, as the term is used herein_dis"or" K_d", means the dissociation ratio of a particular antibody-antigen interaction. As used hereinThe phrase "K_D"means obtained from K_dTo K_a(i.e. K)_d/K_a) The ratio is expressed as the dissociation constant for molar concentration (M). The K of an antibody can be determined using art-recognized methods_DThe value is obtained. Such as using a surface plasmon resonance assay, a cell binding assay, or an equilibrium dialysis assay.

The term "affinity" or "avidity" as used herein refers to the strength of interaction between an antibody and a portion of an antigen referred to as an "epitope" at a single antigenic site. Within each antigenic site, the variable region of the antibody "arm" interacts with the antigen through weak non-covalent forces at multiple atomic positions or amino acid residue atoms of the antibody; generally, the greater the number of such interactions, the greater the affinity of the antibody for the antigen.

Advantageous effects

The invention has the following beneficial effects: provided is a novel CD20 antibody that is capable of better binding to human CD20 protein, inducing strong CDC killing activity while being capable of inducing a certain degree of cell death activity.

Drawings

The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention.

FIG. 1 CDC killing Activity of humanized CD20 antibody

FIG. 2 humanized CD20 antibody induces cell death Activity

Detailed Description

The preferred embodiments of the present invention will be described in conjunction with the accompanying drawings, and it will be understood that they are described herein for the purpose of illustration and explanation and not limitation.

Example 1 anti-CD 20 antibody preparation

BALB/C mice were immunized with NS/0 transfected with human CD 20. Resuspending the cells in PBS, mixing 1:1 with Freund's complete adjuvant, and performing primary immunization by intraperitoneal injection at an immunization dose of 1X10 per mouse⁷And (4) cells. Then every 3 days with the sameDoses of adjuvant-free cells were boosted by intraperitoneal injection. Three days before cell fusion, at 0.5X10⁷Individual cells were shock immunized by intravenous injection. After 3 days, the mice were sacrificed by removing their necks, the spleens were removed, and single cell suspensions were prepared in PBS. Splenocytes were washed 3 times with DMEM medium. Taking mouse myeloma cells SP2/0 in logarithmic growth phase and the separated mouse spleen cells according to the ratio of 1: 4 and washed 2 times with DMEM. Cell fusion was performed by means of PEG fusion. The fused cells were washed 3 times with DEME and resuspended in cell growth medium (RPMI 1640+ 10% FBS +1 XHAT). The cell suspension was plated on 96-well culture plates at 200. mu.l/well, 5X10⁴Cells were cultured in a humidified cell incubator at 37 ℃ and 5% CO 2 for 7 days per well. On day 7, the medium was changed to fresh medium (DMEM + 10% FBS +1 XHAT). After 2-3 days, cell culture supernatants were aspirated and hybridoma clones were screened for binding to human CD20 protein by high-throughput ELISA binding assays. Taking positive clones, and screening monoclonal positive hybridoma cell strains by using a limiting dilution method. And taking the positive hybridoma cells combined with the human CD20 in the ELISA experiment for amplification culture, and freezing and preserving the seeds. The finally selected positive hybridoma cell line was designated as G7B 2.

Example 2 antibody humanization

The hybridoma cells obtained in example 1 were sampled at 5X10⁷Adding 1mL of Trizol, uniformly mixing, transferring into a 1.5mL centrifuge tube, and standing for 5 minutes at room temperature; adding 0.2ml chloroform, oscillating for 15 seconds, standing for 2 minutes, centrifuging for 5 minutes at 4 ℃ at 12000g, taking supernatant, and transferring to a new 1.5ml centrifuge tube; adding 0.5ml of isopropanol, gently mixing the liquid in the tube, standing at room temperature for 10 minutes, centrifuging at 12000g for 15 minutes at 4 ℃, and removing the supernatant; adding 1ml of 75% ethanol, gently washing the precipitate, centrifuging at 4 ℃ and 12000g for 5 minutes, then discarding the supernatant, drying the precipitate in the air, and adding DEPC water to dissolve, thus obtaining the total RNA. Taking total RNA, then synthesizing a first strand cDNA by using a reverse transcription kit (PrimeScript RT Master Mix, purchased from Takara); using cDNA as template, amplifying DNA product containing antibody heavy chain variable region and light chain variable region by PCR, taking 5 mul PCR product to carry out agarose gel electrophoresis detectionPositive samples were purified using a column recovery kit (TIANGEN). Connecting the enzyme-digested product to a pGEM-T carrier, taking 5 mu l of the connecting product to transform competent cells, coating the competent cells on an LB solid culture medium containing antibiotics, and culturing overnight at 37 ℃; and (3) selecting a single colony for amplification on the next day, carrying out colony PCR, selecting a positive clone for sequencing, and obtaining the variable region amino acid sequence of the G7B2 clone according to the sequencing result.

The germline gene sequence with the highest homology to the heavy chain variable region of G7B2, the light chain variable region, was selected as the variable region graft scaffold by sequence alignment (NCBI-Ig blast). After a human antibody framework is selected, key amino acids which can possibly determine the structure in a mouse anti-constant region are predicted through homology modeling, the back mutation design is carried out on the grafted framework region, and the light chain and heavy chain variable region sequence of the humanized antibody after final modification is determined. Antibodies VH and VK domains were synthesized, and the variable regions of the light and heavy chains were amplified separately by PCR method, the heavy chain variable region was directionally cloned into an expression vector containing the signal peptide and the human antibody heavy chain IgG1 constant region (purchased from Invitrogen), and the light chain variable region was directionally cloned into an expression vector containing the signal peptide and the human antibody light chain kappa constant region (purchased from Invitrogen). The plasmid was transformed into competent cells, positive clones were screened according to the screening method described above, and the positive samples were sequenced.

The expression vector of the recombinant antibody heavy and light chains with the correct sequence was amplified and subsequently transiently transfected into HEK293F cells. After 4 days, the cell culture solution was collected, centrifuged at 3000g for 30 minutes, and the supernatant was collected and filtered through a 0.22 μm filter. With 1ml Mab Select^TM SuRe^TMcolumn (from GE Healthcare) purified monoclonal antibodies in 200ml of the clarified supernatant. Mab Select^TM SuRe^TMThe column was first equilibrated with an equilibration buffer (PBS phosphate buffer, pH 7.2). Washing the Mab Select with equilibration buffer after loading^TM SuRe^TMcolumn, volume of equilibration buffer was 5 times the volume of the protein a column bed. Eluting with eluent (0.1M glycine-HCl buffer, pH3.0) bound to Mab Select^TM SuRe^TMMonoclonal antibodies on column. The eluted antibody was collected and 10% (v/v)1.0M Tris-H was addedThe pH was neutralized with Cl buffer. Immediately afterwards, the mixture was dialyzed overnight against PBS phosphate buffer. And (3) collecting the monoclonal antibody after dialysis, performing sterile filtration by using a 0.22-micron filter, and performing sterile storage to obtain the purified CD20 humanized antibody.

The humanized and modified antibody is named as hG7B2-IgG1, and the sequencing result shows that the amino acid sequence of the light and heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO 1 and SEQ ID NO 2; defining CDR sequences according to Kabat, wherein the light chain variable region CDR amino acid sequences and the heavy chain variable region CDR amino acid sequences of the monoclonal antibody are respectively shown as SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7 and SEQ ID NO. 8; the amino acid sequence of the light and heavy chains of the monoclonal antibody is shown as SEQ ID NO. 9 and SEQ ID NO. 10.

Example 3 affinity of humanized CD20 antibody to human CD20

With reference to the amino coupling kit and the human anti-capture kit specification, a human antibody capture Antibody (AHC) was immobilized on the surface of an S-series Sensor Chip (seris S Sensor Chip CM5) by means of amino coupling. And (5) balancing at room temperature for 20-30 min, and loading the chip into an instrument. The antigen was diluted with equilibration buffer, the antigen was diluted 10nM starting with 5 concentration gradients, and 2 zero concentrations (i.e. equilibration buffer) and one replicate concentration (typically the lowest concentration replicate) were set. And (3) diluting the CD20 antibody hG7B2-IgG1 to an experimental working concentration by using an equilibrium buffer solution, and sealing at 2-8 ℃ for later use. The flow rate of the antigen was set at 50. mu.L/min and the binding time was set at 3 min. The flow rate of HBS-EP + buffer is set to be 50 mu L/min, and the dissociation time is set to be 10 min. Use of 3M MgCl₂As a regeneration buffer, the chip was regenerated according to the regeneration procedure. Thereafter, the control antibody Rituximab (whose sequence is referred to IMGT/mAb-DB ID:161) was assayed in the same manner. Calculation of binding Rate (K) by Simultaneous fitting of binding and dissociation sensorgrams_a) And dissociation Rate (K)_d). Equilibrium dissociation constant (K)_d) Using dissociation rate (K)_d) Rate of binding (K)_a) And (4) calculating. The results are shown in table one: the affinity of the antibody of the invention is obviously superior to that of the control antibody Rituximab.

Watch 1

Antibodies	K_a(1/Ms)	K_d(1/s)	K_D(M)
				hG7B2-IgG1	2.46x10⁵	5.31x10^-5	2.15x10^-10
Rituximab	6.31x10⁴	3.45x10^-4	5.46x10^-9

Example 4 CDC killing Activity of humanized CD20 antibody

The Raji cell suspension with vigorous growth was collected and centrifuged at 1000rpm for 5 min. The supernatant was discarded, and the cells were washed 2 times with 1640 medium and resuspended, the cell density was adjusted to 1X10⁶and/mL, taking 100 mu l of cell suspension into a 96-well plate, diluting the CD20 antibody into three concentration gradients of 5 mu g/mL, 1 mu g/mL and 0.2 mu g/mL, adding the three concentration gradients into the cells, culturing for 1h, and simultaneously setting a blank background hole of a cell-free culture medium and a negative control group without the added antibody. Human serum is added according to the volume ratio of 10 percent, after the culture is continued for 4 hours at the temperature of 37 ℃, the non-isotope cytotoxicity test detection kit is used for analysis according to the method provided by the product instruction, and the percentage of the lysed cells is calculated. As shown in FIG. 1, hG7B2-IgG1 was able to induce more potent CDC killing.

Example 5 humanized CD20 antibody induces cell death Activity

The Raji cell suspension with vigorous growth was collected and centrifuged at 1000rpm for 5 min. The supernatant was discarded, and the cells were washed 2 times with 1640 medium and resuspended, the cell density was adjusted to 1X10⁶and/mL, 100 mu l of cell suspension is taken into a 96-well plate, the CD20 antibody is diluted into three concentration gradients of 5 mu g/mL, 1 mu g/mL and 0.2 mu g/mL, the three concentration gradients are added into the cells for co-culture for 48 hours, meanwhile, a blank background hole of a cell-free culture medium and a negative control group without the antibody are arranged, and after the cells are washed twice, the cell death percentage is detected by an Annexin V/PI kit (product of BD company) according to the product instruction. As shown in FIG. 2, hG7B2-IgG1 and Rituximab were able to induce almost the same degree of cell death induction.

Sequence listing

<110> Beijing Guangdong Biotechnology Ltd

<120> CD20 antibody and application thereof in treating cancer

<160> 10

<170> SIPOSequenceListing 1.0

<210> 1

<211> 109

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 1

Asp Ile Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln

1 5 10 15

Ser Val Thr Ile Ser Cys Ser Ala Ile Asp Gly Asn Cys Phe Asn Lys

20 25 30

Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile

35 40 45

Tyr Asp Ala Ser Lys Arg Cys Thr Gly Ile Pro Glu Arg Phe Ser Gly

50 55 60

Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala

65 70 75 80

Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Ala Ser Lys Asp Ala Pro

85 90 95

Ile Thr Thr Phe Gly Arg Gly Thr Lys Leu Thr Val Leu

100 105

<210> 2

<211> 117

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 2

Gln Val Gln Leu Val Gln Ser Gly Gly Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Arg Phe Thr Ser Gly

20 25 30

Lys Asn Ala Val Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp

35 40 45

Met Gly Gly Ile Ala Thr Gly Lys Phe Asn Leu Ser Val Asp Leu Gln

50 55 60

Gly Arg Leu Thr Leu Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met

65 70 75 80

Glu Leu Gly Ser Leu Arg Pro Asp Asp Thr Ala Val Tyr Tyr Cys Thr

85 90 95

Arg Asp Ile Arg Leu Tyr Ala Gly Asp Tyr Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser

115

<210> 3

<211> 12

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 3

Ser Ala Ile Asp Gly Asn Cys Phe Asn Lys Val Ser

1 5 10

<210> 4

<211> 7

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 4

Asp Ala Ser Lys Arg Cys Thr

1 5

<210> 5

<211> 11

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 5

Gln Ala Ala Ser Lys Asp Ala Pro Ile Thr Thr

1 5 10

<210> 6

<211> 6

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 6

Ser Gly Lys Asn Ala Val

1 5

<210> 7

<211> 15

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 7

Gly Ile Ala Thr Gly Lys Phe Asn Leu Ser Val Asp Leu Gln Gly

1 5 10 15

<210> 8

<211> 9

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 8

Asp Ile Arg Leu Tyr Ala Gly Asp Tyr

1 5

<210> 9

<211> 216

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 9

Asp Ile Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln

1 5 10 15

Ser Val Thr Ile Ser Cys Ser Ala Ile Asp Gly Asn Cys Phe Asn Lys

20 25 30

Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile

35 40 45

Tyr Asp Ala Ser Lys Arg Cys Thr Gly Ile Pro Glu Arg Phe Ser Gly

50 55 60

Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala

65 70 75 80

Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Ala Ser Lys Asp Ala Pro

85 90 95

Ile Thr Thr Phe Gly Arg Gly Thr Lys Leu Thr Val Leu Arg Thr Val

100 105 110

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys

115 120 125

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg

130 135 140

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn

145 150 155 160

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser

165 170 175

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys

180 185 190

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr

195 200 205

Lys Ser Phe Asn Arg Gly Glu Cys

210 215

<210> 10

<211> 447

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 10

Gln Val Gln Leu Val Gln Ser Gly Gly Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Arg Phe Thr Ser Gly

20 25 30

Lys Asn Ala Val Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp

35 40 45

Met Gly Gly Ile Ala Thr Gly Lys Phe Asn Leu Ser Val Asp Leu Gln

50 55 60

Gly Arg Leu Thr Leu Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met

65 70 75 80

Glu Leu Gly Ser Leu Arg Pro Asp Asp Thr Ala Val Tyr Tyr Cys Thr

85 90 95

Arg Asp Ile Arg Leu Tyr Ala Gly Asp Tyr Trp Gly Gln Gly Thr Leu

100 105 110

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu

115 120 125

Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys

130 135 140

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser

145 150 155 160

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser

165 170 175

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser

180 185 190

Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn

195 200 205

Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His

210 215 220

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val

225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr

245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu

260 265 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

275 280 285

Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser

290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys

305 310 315 320

Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile

325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro

340 345 350

Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu

355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn

370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser

385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg

405 410 415

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu

420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

Claims

1. An anti-CD 20 antibody comprising a light chain variable region comprising a CDR1 region, a CDR2 region and a CDR3 region and a heavy chain variable region wherein the light chain CDR1, CDR2 and CDR3 regions are set forth in SEQ ID NOs 3, 4 and 5, respectively; the heavy chain variable region comprises a CDR1 region, a CDR2 region and a CDR3 region, and the heavy chain CDR1 region, the CDR2 region and the CDR3 region are shown in SEQ ID NO 6, 7 and 8, respectively.

2. The anti-CD 20 antibody of claim 1, comprising a light chain variable region sequence as set forth in SEQ ID No. 1 and a heavy chain variable region sequence as set forth in SEQ ID No. 2.

3. The anti-CD 20 antibody of any one of claims 1-2, comprising a light chain 9 as set forth in SEQ ID No. 9 and a heavy chain as set forth in SEQ ID No. 10.

4. The anti-CD 20 antibody according to any one of claims 1-2, wherein: the antibody further comprises a heavy chain constant region selected from IgG1, IgG2, IgG3, or IgG4 and a light chain constant region selected from a kappa or Lambda subtype.

5. The anti-CD 20 antibody according to any one of claims 1-2, wherein: the antibody heavy chain constant region is more preferably IgG1 and the antibody light chain constant region is more preferably kappa.

6. An expression vector that replicates in a prokaryotic or eukaryotic cell line, characterized in that: encoding an antibody according to any one of claims 1 to 5.

7. A pharmaceutical composition characterized by comprising the antibody of any one of claims 1-5 and a pharmaceutically acceptable carrier.

8. Use of the pharmaceutical composition of the anti-CD 20 antibody of any one of claims 1-5 in the manufacture of a medicament for the treatment of a CD 20-related disorder.

9. The use of claim 8, wherein the cancer is selected from non-Hodgkin's lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Acute Lymphoid Leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), Hodgkin's Lymphoma (HL), gastric cancer peritoneal metastasis, liver cancer, leukemia, renal tumors, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, large intestine cancer, cervical cancer, ovarian cancer, lymphatic cancer, nasopharyngeal cancer, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC), brain glioma, endometrial cancer, or a combination thereof.